LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Search

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

80.73 0.2

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78.6

Max

82.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-254M

-103M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+15.33% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.1B

14B

Ankstesnė atidarymo kaina

80.53

Ankstesnė uždarymo kaina

80.73

Naujienos nuotaikos

By Acuity

58%

42%

299 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-25 23:25; UTC

Karštos akcijos

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026-02-25 23:15; UTC

Uždarbis

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026-02-25 23:54; UTC

Rinkos pokalbiai

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026-02-25 23:47; UTC

Uždarbis

Ferrovial 4Q Net EUR197M >FER.MC

2026-02-25 23:45; UTC

Uždarbis

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026-02-25 23:42; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026-02-25 23:38; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Company's Business Operations Remain Normal >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY EPS CNY47.67 >TCOM

2026-02-25 23:06; UTC

Uždarbis

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026-02-25 23:01; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026-02-25 23:00; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2026-02-25 23:00; UTC

Rinkos pokalbiai
Uždarbis

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026-02-25 22:56; UTC

Rinkos pokalbiai
Uždarbis

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026-02-25 22:43; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026-02-25 22:40; UTC

Rinkos pokalbiai
Uždarbis

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026-02-25 22:40; UTC

Uždarbis

Karoon Energy Says Search for New CFO Well Advanced

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says CFO Ray Church to Leave Company

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026-02-25 22:38; UTC

Uždarbis

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

15.33% į viršų

12 mėnesių prognozė

Vidutinis 98.55 USD  15.33%

Aukščiausias 110 USD

Žemiausias 87 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

11

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

299 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat